HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women.
BACKGROUND The main goals of estrogen replacement therapy ( ERT ) are the prevention of osteoporosis and cardioprotection and the improvement of quality of life ( QL ) . And rogens and tibolone therapy may increase bone mineral density ( BMD ) to a greater extent than ERT and offer an increase in QL . Lipid and cardiovascular effects , however , are still a major concern . AIM To evaluate whether the addition of a weak and rogen to ERT may improve postmenopausal bone loss and sexual activity without adverse effects on lipid pattern and to compare these effects with those observed after tibolone therapy . SUBJECTS AND METHODS This prospect i ve study enrolled 120 surgical postmenopausal women ; of these , 96 completed the 1-year follow-up . Patients were allocated to one of four groups . The first group ( A ; n = 23 ) received 4 mg of estradiol valerate plus 200 mg of enanthate of dihydro and rosterone i m monthly . The second group ( E ; n = 26 ) received 50 microg/day of transdermal 17-b-estradiol continuously ; the third ( T ; n = 23 ) received 2.5 mg of tibolone every day ; and finally , the fourth group ( C ; n = 24 ) constituted a treatment-free control group . Bone mass ( dual X-ray absorptiometry ) , serum total cholesterol , HDL , LDL , triglycerides , apolipoproteins A1 and B and sexual activity were evaluated before starting therapy and at the end of follow-up . RESULTS All active treatment groups showed an increase in BMD . This increase was higher in the A treatment group ( 4.08 % P < 0.01 ) . Sexuality improved significantly with therapy ; however , tibolone and and rogens increased scores to a greater extent than ERT . And rogen therapy was associated with significant increases in total cholesterol , LDL and triglycerides . Cholesterol and LDL fall into groups E and T , HDL into groups A and T and triglycerides in group T only . CONCLUSION The combined regimen of and rogens and ERT increased vertebral bone mass and enhance sexual activity in postmenopausal women equal to that of tibolone and to a greater extent than ERT alone ; its effects on lipids , however , are clearly adverse
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .